Medicine and Dentistry
Lung
100%
Cystic Fibrosis
92%
Lung Transplantation
32%
Patient Registry
31%
Severe Acute Respiratory Syndrome Coronavirus 2
30%
Oxalic Acid
30%
Diuresis
30%
Kidney Graft
30%
Graft Survival
30%
Forced Expiratory Volume
22%
Disease Exacerbation
21%
Silo-Filler's Disease
18%
Prospective Cohort Study
18%
Omicron Coronavirus Variant
17%
Environmental Exposure
17%
Monoclonal Antibody Therapy
15%
Immunocompromised Patient
15%
Papillary Thyroid Cancer
15%
Predictive Factor
15%
Clinical Significance
15%
Ivacaftor
15%
Radius Fracture
15%
Compartment Syndrome
15%
Patient-Reported Outcome
15%
Numeric Rating Scale
15%
Distal Radius Fracture
15%
Randomized Controlled Trial
15%
Infection
15%
Immunoglobulin G
15%
Nutritional Status
15%
Cohort Analysis
15%
Material Deprivation
14%
Monoclonal Antibody
10%
Body Mass Index
10%
Predictor
8%
Immunoglobulin G Antibody
8%
Graft Failure
8%
COVID-19
7%
Viral Clearance
7%
Splinting
7%
Nonunion
7%
Logistic Regression Analysis
7%
Adverse Event
7%
Arm
7%
Closed Reduction (Procedure)
7%
Odds Ratio
7%
Pediatrics Patient
7%
Atmospheric Aerosols
7%
Principal Component Analysis
6%
Recurrent Disease
6%
Immunology and Microbiology
COVID-19
55%
Human Immunodeficiency Virus
46%
Severe Acute Respiratory Syndrome Coronavirus 2
35%
Booster Dose
34%
Immunogenicity
30%
Lung Transplantation
30%
Diuresis
30%
Spike
23%
Omicron Coronavirus Variant
17%
CD4 Lymphocyte Count
16%
Monoclonal Antibody Therapy
15%
Immunocompromised Patient
15%
Alemtuzumab
15%
Kidney Graft Rejection
15%
Immunoglobulin G
15%
Glucocorticoid
15%
Particulate Matter
15%
Forced Expiratory Volume
15%
Vaccine Immunogenicity
15%
Immunoglobulin G Antibody
10%
Monoclonal Antibody
10%
Precursor
8%
T Cell
8%
Viral Clearance
7%
Digestive System
7%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
46%
Cystic Fibrosis
46%
SARS Coronavirus
32%
Graft Failure
30%
Immunogenicity
30%
Prospective Cohort Study
25%
Patient Registry
24%
Infection
21%
Monoclonal Antibody
15%
Alemtuzumab
15%
Immunocompromised Patient
15%
Kidney Graft Rejection
15%
Lung Fibrosis
15%
Immunoglobulin G
15%
Recurrent Disease
15%
Glucocorticoid
15%
Ivacaftor
15%
Cohort Study
13%
Disease Exacerbation
11%
Glyoxylic Acid
10%
Fibrosing Alveolitis
9%
Immunoglobulin G Antibody
8%
Viral Clearance
7%
Clinical Trial
7%
Messenger RNA
6%
Monotherapy
5%